Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B

Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in its investigational stem cell therapy, Lomecel-B. The company, which focuses on developing cellular therapies for life-threatening and age-related conditions, announced a 237% year-over-year revenue increase for 2024. This growth was prima